镭-223降低骨转移灶PD-L1表达:89Zr-atezolizumab PET与免疫组化相关性研究
这项前瞻性多中心研究纳入28例以骨转移为主的mCRPC患者,按标准治疗接受镭-223,用68Ga-PSMA与89Zr-atezolizumab PET序贯显像并以免疫组化和流式细胞术分析免疫状态。结果显示镭-223三周期后骨转移灶89Zr-atezolizumab摄取下降,肿瘤组织与血中淋巴细胞数同步减少,提示α射线改变免疫微环境、可能削弱PD-(L)1抑制剂疗效。
要点
- 镭-223三周期后骨转移灶89Zr-atezolizumab摄取下降,PD-L1表达在体降低。
- 该下降不依赖68Ga-PSMA PET的疗效反应,肿瘤及血淋巴细胞同步减少。
- 提示镭-223可能不利于后续PD-(L)1抑制剂治疗。
核心结论
- 镭-223治疗mCRPC骨转移使在体PD-L1表达显著下降,并减少骨转移灶与血中免疫细胞,提示α射线改变免疫微环境、可能降低PD-(L)1抑制剂疗效。
研究设计与样本
- 前瞻性多中心研究(ICTRP NL-OMON26890),28例mCRPC且以骨转移为主的患者按标准治疗接受镭-223。
- 主要终点为无失败生存(FFS),采用68Ga-PSMA与89Zr-atezolizumab PET序贯显像量化全身PD-L1表达(SUVmean/max)。
- 配对PET分析9例,骨转移灶活检与血样分别用(多重)免疫组化与流式细胞术评估免疫状态,序贯活检分析2例。
主要发现
- 68Ga-PSMA阳性骨转移灶中89Zr-atezolizumab摄取在患者内与患者间异质性高。
- 全部68Ga-PSMA阳性骨病灶总体积中,89Zr-atezolizumab的SUVmean中位数基线为2.5(IQR 0.9-3.4),镭-223三周期后为0.9(IQR 0.5-2.5),均高于骨髓生理性摄取。
- 镭-223三周期后骨转移灶89Zr-atezolizumab摄取下降,且不依赖68Ga-PSMA PET的疗效反应,同时肿瘤组织与血中淋巴细胞数减少。
临床怎么用
- 对拟接受或已接受镭-223的mCRPC骨转移患者,应认识到PD-L1在体表达可能下降,联合或序贯PD-(L)1抑制剂需谨慎评估。
- 89Zr-atezolizumab PET可用于在体量化PD-L1表达变化,但患者内与患者间异质性高,需结合活检与血液免疫分析综合判断。
局限性
- 配对PET分析仅9例、序贯活检分析仅2例,纵向免疫组化证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Most patients with metastatic castration-resistant prostate cancer (mCRPC) do not benefit from treatment with immune checkpoint inhibitors targeting programmed cell death (ligand) 1 (PD-(L)1). Radiation might improve response to immunotherapy by increasing the immunogenicity of prostate cancer. The objective of this study was to investigate radium-223-mediated changes in the micro- and macroenvironment of mCRPC. METHODS: In this prospective, multicenter study (ICTRP NL-OMON26890), 28 patients with mCRPC and predominantly bone metastases were treated with radium-223, according to standard-of-care. Primary endpoint was failure-free survival (FFS). Imaging included sequential positron emission tomography (PET) with gallium-68 prostate-specific membrane antigen (68Ga-PSMA) and zirconium-89 atezolizumab (89Zr-atezolizumab) to quantify whole-body expression of PD-L1 in vivo (SUVmean/max). Paired PET analysis included nine patients. The immune status of patients was characterized in biopsies from bone metastases and in blood using (multiplex) immunohistochemistry (IHC) and flow cytometry, respectively. Sequential biopsy analysis included two patients. RESULTS: 89Zr-atezolizumab uptake in 68Ga-PSMA positive bone metastases showed high intra- and inter-patient heterogeneity. In the total volume of 68Ga-PSMA-positive bone lesions, the median SUVmean of 89Zr-atezolizumab was 2.5 (IQR 0.9-3.4) at baseline and 0.9 (IQR 0.5-2.5) after three cycles of radium-223, which was higher than the physiological uptake in bone marrow at baseline and after treatment with radium-223. After three cycles of radium-223, 89Zr-atezolizumab uptake decreased in bone metastases, independent of response on 68Ga-PSMA PET, and the number of lymphocytes in tumor tissue and blood decreased concomitantly. CONCLUSIONS: Treatment of mCRPC bone metastases with radium-223 results in a significant decrease of in vivo PD-L1-expression on PET imaging and a decrease in immune cells in bone metastases and blood. These findings indicate that treatment with alpha emitting radium-223 alters the immune microenvironment, thereby potentially reducing the efficacy of PD-(L)1 inhibitors. Most patients with metastatic castration-resistant prostate cancer (mCRPC) do not benefit from treatment with immune checkpoint inhibitors targeting programmed cell death (ligand) 1 (PD-(L)1). By increasing the immunogenicity of the immunosuppressive prostate cancer microenvironment, radiation might improve response to immunotherapy. Therefore, we aimed to gain insight into the immune response to the radionuclide radium-223. In this prospective study, 28 patients with mCRPC were treated with radium-223. Using positron emission tomography (PET) with gallium-68 prostate-specific membrane antigen (68Ga-PSMA) and zirconium-89 atezolizumab (89Zr-atezolizumab), we showed that whole-body expression of PD-L1 decreased after treatment with radium-223. In addition, the number of lymphocytes in tumor tissue and blood decreased. These findings indicate that treatment with alpha emitting radium-223 negatively affects the immune microenvironment, thereby impeding treatment with PD-(L)1 inhibitors.
引用
- Ling SW, de Jong A, Gorris M, et al. Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation. Eur J Nucl Med Mol Imaging. 2026. PMID: 42728370. doi:10.1007/s00259-026-08175-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。